Clinical Trial Update: A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated three lots of an investigational RSV vaccine in adults aged 60+, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Investigational RSV vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED | Results posted: 2023-02-15